Abstract
Although germline de novo copy number variants are a known cause of autism spectrum disorder (ASD), the contribution of mosaic (early-developmental) copy number variants (mCNVs) has not been explored. Here, we assessed the contribution of mCNVs to ASD by ascertaining mCNVs in genotype array intensity data from 12,077 ASD probands and 5,500 unaffected siblings in the Simons Simplex Collection (SSC) and Simons Powering Autism Research for Knowledge (SPARK) cohorts. We detected 46 mCNVs in probands and 19 mCNVs in siblings ranging from 49 kb to 249 Mb and affecting 2.8-73.8% of cells. In both cohorts, probands carried a significant burden of large (>4 Mb) mCNVs (P = 0.043 and P = 6.6 × 10−3 in SSC and SPARK, respectively), which were present in a total of 25 probands but only 1 sibling (OR=11.4, 95% CI=1.5-84.2). Surprisingly, we did not observe mosaic analogues of the short de novo CNVs recurrently observed in ASD. Event size positively correlated with severity of ASD symptoms (P = 0.016), and four probands exhibited clinical symptoms consistent with syndromes previously associated with genes or regions disrupted by their respective mosaic mutations. In analyses of post-mortem brain tissue from 60 additional probands, we further detected and experimentally validated two mCNVs including a complex 10.3 Mb duplication on chromosome 2. These results indicate that mosaic CNVs contribute a previously unexplained component of ASD risk.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
P.-R.L. was supported by US NIH grant DP2 ES030554, a Burroughs Wellcome Fund Career Award at the Scientific Interfaces, the Next Generation Fund at the Broad Institute of MIT and Harvard, a Glenn Foundation for Medical Research and AFAR Grants for Junior Faculty award, and a Sloan Research Fellowship. M.A.S. and B.B. were supported by a John W. Jarve Seed Grant from MIT. B.B. was additionally supported by NIH grant R01-GM108348. C.A.W. is supported by the Allen Discovery Center program through The Paul G. Allen Frontiers Group, and grants from the NINDS (R01 NS032457). C.A.W and P.J.P were supported by grant U01MH106883 from the NIMH. C.A.W. is an Investigator of the Howard Hughes Medical Institute. R.E.R. was supported by the Stuart H.Q. and Victoria Quan Fellowship in Neurobiology, and by the Harvard/MIT MD-PhD program (T32GM007753). C.M.D is supported by a NIMH Translational Post-doctoral Training Program in Neurodevelopment (T32 MH112510).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵§ These authors jointly supervised this work.
Data Availability
Genotype array data for SSC and SPARK cohorts are available from SFARI Base for approved researchers. Whole-genome sequencing data will be available from the National Institute of Mental Health Data Archive (DOI: 10.15154/1503337).
